

GraÅ»yna Sypniewska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7827459/publications.pdf>

Version: 2024-02-01

53
papers

2,210
citations

331670

21
h-index

223800

46
g-index

53
all docs

53
docs citations

53
times ranked

3662
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationships between Bone Turnover Markers and Factors Associated with Metabolic Syndrome in Prepubertal Girls and Boys. <i>Nutrients</i> , 2022, 14, 1205.	4.1	6
2	The Kynurenine Pathway in Obese Middle-Aged Women with Normoglycemia and Type 2 Diabetes. <i>Metabolites</i> , 2022, 12, 492.	2.9	8
3	Serum ANGPTL8 and ANGPTL3 as Predictors of Triglyceride Elevation in Adult Women. <i>Metabolites</i> , 2022, 12, 539.	2.9	3
4	Cardioprotective Effects of Nutraceuticals: Focus on Omega-3 Polyunsaturated Fatty Acids. <i>Nutrients</i> , 2021, 13, 3184.	4.1	4
5	The Association between Branched-Chain Amino Acids (BCAAs) and Cardiometabolic Risk Factors in Middle-Aged Caucasian Women Stratified According to Glycemic Status. <i>Nutrients</i> , 2021, 13, 3307.	4.1	10
6	Low Serum 25-hydroxyvitamin D Level Does Not Adversely Affect Bone Turnover in Prepubertal Children. <i>Nutrients</i> , 2021, 13, 3324.	4.1	1
7	Effect of fasting hyperglycemia and insulin resistance on bone turnover markers in children aged 9–11 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108000.	2.3	6
8	Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity. <i>Nutrients</i> , 2021, 13, 4339.	4.1	5
9	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. <i>Diagnostyka Laboratoryjna i Wiadomości PTDL</i> , 2021, 57, 1-99.	0.1	0
10	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. <i>Archives of Medical Science</i> , 2021, 17, 1447-1547.	0.9	78
11	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 496-517.	2.3	119
12	Bone health and hyperglycemia in pediatric populations. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 444-457.	6.1	5
13	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.8	137
14	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1161-1168.	2.3	23
15	Association between Fasting Glucose Concentration, Lipid Profile and 25(OH)D Status in Children Aged 9–11. <i>Nutrients</i> , 2018, 10, 1359.	4.1	10
16	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189
17	Non-fasting lipid profile determination in presumably healthy children: Impact on the assessment of lipid abnormalities. <i>PLoS ONE</i> , 2018, 13, e0198433.	2.5	7
18	High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 143-172.	6.1	51

#	ARTICLE	IF	CITATIONS
19	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. <i>Clinical Biochemistry</i> , 2017, 50, 599-604.	1.9	14
20	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints—A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2016, 62, 930-946.	3.2	145
21	Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2016, 462, 193-200.	1.1	7
22	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>European Heart Journal</i> , 2016, 37, 1944-1958.	2.2	542
23	Gender differences in association of serum nesfatin-1 with selected metabolic risk factors in normoglycemic subjects: A preliminary study. <i>Journal of Endocrinology</i> , 2017, 194, 183-192.	1.8	4
24	Laboratory assessment of cardiometabolic risk in overweight and obese children. <i>Clinical Biochemistry</i> , 2015, 48, 370-376.	1.9	27
25	Defining normality in a European multinational cohort: Critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. <i>International Journal of Cardiology</i> , 2015, 187, 256-263.	1.7	41
26	Metabolic Syndrome and Menopause. <i>Advances in Clinical Chemistry</i> , 2015, 72, 1-75.	3.7	158
27	The Putative Role of Vitamin D in Essential Hypertension: Stepping Into the Light. <i>American Journal of Hypertension</i> , 2014, 27, 987-988.	2.0	0
28	European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1657-65.	2.3	117
29	25-Hydroxyvitamin D, Biomarkers of Endothelial Dysfunction and Subclinical Organ Damage in Adults With Hypertension. <i>American Journal of Hypertension</i> , 2014, 27, 114-121.	2.0	30
30	Association of FSH with metabolic syndrome in postmenopausal women: a comparison with CRP, adiponectin and leptin. <i>Biomarkers in Medicine</i> , 2014, 8, 921-930.	1.4	28
31	A-FABP Concentration Is More Strongly Associated with Cardiometabolic Risk Factors and the Occurrence of Metabolic Syndrome in Premenopausal Than in Postmenopausal Middle-Aged Women. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	4
32	Secreted frizzled-related protein 4 (SFRP4) and fractalkine (CX3CL1) — Potential new biomarkers for β-cell dysfunction and diabetes. <i>Clinical Biochemistry</i> , 2014, 47, 529-532.	1.9	29
33	Critical appraisal of inflammatory markers in cardiovascular risk stratification. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 263-279.	6.1	67
34	Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 177-185.	2.3	65
35	A-FABP and its association with atherogenic risk profile and insulin resistance in young overweight and obese women. <i>Biomarkers in Medicine</i> , 2013, 7, 723-730.	1.4	8
36	Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-6.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Value of C-Reactive Protein as a Risk Factor for Acute Coronary Syndrome: A Comparison with Apolipoprotein Concentrations and Lipid Profile. <i>Mediators of Inflammation</i> , 2012, 2012, 1-10.	3.0	19
38	Association of follicle-stimulating hormone and sex hormone binding globulin with the metabolic syndrome in postmenopausal women. <i>Clinical Biochemistry</i> , 2012, 45, 703-706.	1.9	31
39	Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2011, 41, 667-671.	3.4	23
40	Comparison between C-reactive protein and adipocyte fatty acid-binding protein as a component of metabolic syndrome in middle-aged women. <i>Clinical Biochemistry</i> , 2011, 44, 304-306.	1.9	10
41	The quality of the extra-analytical phase of laboratory practice in some developing European countries and Mexico – a multicentric study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 215-228.	2.3	27
42	How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes. <i>Journal of Medical Biochemistry</i> , 2011, 30, 237-243.	1.7	13
43	Is there an association of allergy and cardiovascular disease?. <i>Biochemia Medica</i> , 2011, 21, 210-218.	2.7	14
44	Effect of second and third generation oral contraceptives on C-reactive protein, lipids and apolipoproteins in young, non-obese, non-smoking apparently healthy women. <i>Clinical Biochemistry</i> , 2010, 43, 626-628.	1.9	12
45	Biochemical Markers of Bone Cell Activity in Children with Type 1 Diabetes Mellitus. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2010, 23, 81-6.	0.9	40
46	The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes. <i>Journal of Medical Biochemistry</i> , 2009, 28, 293-299.	1.7	9
47	Local Calcitriol Injections as a Suppressive Treatment of Secondary Hyperparathyroidism in Chronic Dialysis Patients. <i>Renal Failure</i> , 2007, 29, 941-945.	2.1	1
48	Association of C-Reactive Protein and Other Markers of Inflammation with Risk of Complications in Diabetic Subjects. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2006, 17, 8-11.	0.7	3
49	Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. <i>International Journal of Molecular Medicine</i> , 2005, 16, 173-80.	4.0	21
50	Bone turnover markers and cytokines in joint fluid: Analyses in 10 patients with loose hip prosthesis and 39 with coxarthrosis. <i>Acta Orthopaedica</i> , 2002, 73, 518-522.	1.4	14
51	Bone Turnover Markers and Estradiol Level in Postmenopausal Women. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 1115-9.	2.3	10
52	Increased DNA synthesis in adipocytes and capillary endothelium in rat adipose tissue during overfeeding. <i>European Journal of Clinical Investigation</i> , 1987, 17, 202-207.	3.4	9
53	Microalbuminuria and risk of cardiovascular diseases in patients with diabetes and hypertension. <i>Biochemia Medica</i> , 0, , 25-34.	2.7	1